The , p.E318G Variant Increases the Risk of Alzheimer's Disease in -ε4 Carriers

English version České info

The primary constituents of plaques (Aβ42/Aβ40) and neurofibrillary tangles (tau and phosphorylated forms of tau [ptau]) are the current leading diagnostic and prognostic cerebrospinal fluid (CSF) biomarkers for AD. In this study, we performed deep sequencing of APP, PSEN1, PSEN2, GRN, APOE and MAPT genes in individuals with extreme CSF Aβ42, tau, or ptau levels. One known pathogenic mutation (PSEN1 p.A426P), four high-risk variants for AD (APOE p.L46P, MAPT p.A152T, PSEN2 p.R62H and p.R71W) and nine novel variants were identified. Surprisingly, a coding variant in PSEN1, p.E318G (rs17125721-G) exhibited a significant association with high CSF tau (p = 9.2×10⁻⁴) and ptau (p = 1.8×10⁻³) levels. The association of the p.E318G variant with Aβ deposition was observed in APOE-ε4 allele carriers. Furthermore, we found that in a large case-control series (n = 5,161) individuals who are APOE-ε4 carriers and carry the p.E318G variant are at a risk of developing AD (OR = 10.7, 95% CI = 4.7–24.6) that is similar to APOE-ε4 homozygous (OR = 9.9, 95% CI = 7.2.9–13.6), and double the risk for APOE-ε4 carriers that do not carry p.E318G (OR = 3.9, 95% CI = 3.4–4.4). The p.E318G variant is present in 5.3% (n = 30) of the families from a large clinical series of LOAD families (n = 565) and exhibited a higher frequency in familial LOAD (MAF = 2.5%) than in sporadic LOAD (MAF = 1.6%) (p = 0.02). Additionally, we found that in the presence of at least one APOE-ε4 allele, p.E318G is associated with more Aβ plaques and faster cognitive decline. We demonstrate that the effect of PSEN1, p.E318G on AD susceptibility is largely dependent on an interaction with APOE-ε4 and mediated by an increased burden of Aβ deposition.

Vyšlo v časopise: The , p.E318G Variant Increases the Risk of Alzheimer's Disease in -ε4 Carriers. PLoS Genet 9(8): e32767. doi:10.1371/journal.pgen.1003685
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003685

Souhrn

Zdroje

1. HoltzmanDM, MorrisJC, GoateAM (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr71.

2. 2009 Alzheimer's disease facts and figures. Alzheimers Dement 5: 234–270.

3. GoateA, Chartier-HarlinMC, MullanM, BrownJ, CrawfordF, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704–706.

4. GatzM, MortimerJA, FratiglioniL, JohanssonB, BergS, et al. (2006) Potentially modifiable risk factors for dementia in identical twins. Alzheimers Dement 2: 110–117.

5. SoHC, GuiAH, ChernySS, ShamPC (2011) Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 35: 310–317.

6. ShulmanJM, ChibnikLB, AubinC, SchneiderJA, BennettDA, et al. (2010) Intermediate phenotypes identify divergent pathways to Alzheimer's disease. PLoS One 5: e11244.

7. TennessenJA, BighamAW, O'ConnorTD, FuW, KennyEE, et al. (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337: 64–69.

8. LiuY, MaxwellS, FengT, ZhuX, ElstonRC, et al. (2012) Gene, pathway and network frameworks to identify epistatic interactions of single nucleotide polymorphisms derived from GWAS data. BMC Syst Biol 6 Suppl 3: S15.

9. NolanDK, SuttonB, HaynesC, JohnsonJ, SebekJ, et al. (2012) Fine mapping of a linkage peak with integration of lipid traits identifies novel coronary artery disease genes on chromosome 5. BMC Genet 13: 12.

10. CohenJC, KissRS, PertsemlidisA, MarcelYL, McPhersonR, et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869–872.

11. KauweJS, CruchagaC, BertelsenS, MayoK, LatuW, et al. (2010) Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J Alzheimers Dis 21: 833–842.

12. HoltzmanDM (2011) CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 32 Suppl 1: S4–9.

13. BatemanRJ, XiongC, BenzingerTL, FaganAM, GoateA, et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795–804.

14. CruchagaC, KauweJS, NowotnyP, BalesK, PickeringEH, et al. (2012) Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet 21: 4558–4571.

15. ScheunerD, EckmanC, JensenM, SongX, CitronM, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864–870.

16. ForteaJ, LladoA, BoschB, AntonellA, OlivaR, et al. (2011) Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegener Dis 8: 202–207.

17. CruchagaC, KauweJS, MayoK, SpiegelN, BertelsenS, et al. (2010) SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 6: e1001101.

18. KauweJS, CruchagaC, MayoK, FenoglioC, BertelsenS, et al. (2008) Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A 105: 8050–8054.

19. KauweJS, WangJ, MayoK, MorrisJC, FaganAM, et al. (2009) Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 10: 13–17.

20. WallonD, RousseauS, Rovelet-LecruxA, Quillard-MuraineM, Guyant-MarechalL, et al. (2012) The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis 30: 847–856.

21. BalasaM, Vidal-PineiroD, LladoA, AntonellA, BoschB, et al. (2012) PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-beta42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. J Alzheimers Dis 30: 605–616.

22. RingmanJM, GylysKH, MedinaLD, FoxM, KepeV, et al. (2011) Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett 487: 287–292.

23. JackCRJr, KnopmanDS, JagustWJ, ShawLM, AisenPS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119–128.

24. GuerreiroR, WojtasA, BrasJ, CarrasquilloM, RogaevaE, et al. (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117–127.

25. JonssonT, StefanssonH, SteinbergS, JonsdottirI, JonssonPV, et al. (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107–116.

26. BenitezBA, CooperB, PastorP, JinSC, LorenzoE, et al. (2013) TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging 34: 1711 e1715–1717.

27. GerrishA, RussoG, RichardsA, MoskvinaV, IvanovD, et al. (2012) The role of variation at AbetaPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis 28: 377–387.

28. CruchagaC, HallerG, ChakravertyS, MayoK, VallaniaFL, et al. (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 7: e31039.

29. KauweJS, JacquartS, ChakravertyS, WangJ, MayoK, et al. (2007) Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol 61: 446–453.

30. AdzhubeiIA, SchmidtS, PeshkinL, RamenskyVE, GerasimovaA, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249.

31. PoorkajP, SharmaV, AndersonL, NemensE, AlonsoME, et al. (1998) Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene. Hum Mutat 11: 216–221.

32. ScacchiR, GambinaG, FerrariG, CorboRM (2003) Screening of two mutations at exon 3 of the apolipoprotein E gene (sites 28 and 42) in a sample of patients with sporadic late-onset Alzheimer's disease. Neurobiol Aging 24: 339–343.

33. CoppolaG, ChinnathambiS, LeeJJ, DombroskiBA, BakerMC, et al. (2012) Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 21: 3500–3512.

34. CrutsM, TheunsJ, Van BroeckhovenC (2012) Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 33: 1340–1344.

35. ShawLM, VandersticheleH, Knapik-CzajkaM, ClarkCM, AisenPS, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403–413.

36. WelgeV, FiegeO, LewczukP, MollenhauerB, EsselmannH, et al. (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116: 203–212.

37. FaganAM, RoeCM, XiongC, MintunMA, MorrisJC, et al. (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343–349.

38. GaoX, BeckerLC, BeckerDM, StarmerJD, ProvinceMA (2010) Avoiding the high Bonferroni penalty in genome-wide association studies. Genet Epidemiol 34: 100–105.

39. FaganAM, HeadD, ShahAR, MarcusD, MintunM, et al. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65: 176–183.

40. PastorP, RoeCM, VillegasA, BedoyaG, ChakravertyS, et al. (2003) Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 54: 163–169.

41. WijsmanEM, DawEW, YuX, SteinbartEJ, NochlinD, et al. (2005) APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet 132B: 14–20.

42. AlbaniD, RoiterI, ArtusoV, BatelliS, PratoF, et al. (2007) Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiol Aging 28: 1682–1688.

43. DermautB, CrutsM, SlooterAJ, Van GestelS, De JongheC, et al. (1999) The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease. Am J Hum Genet 64: 290–292.

44. TaddeiK, FisherC, LawsSM, MartinsG, PatonA, et al. (2002) Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Mol Psychiatry 7: 776–781.

45. LawsSM, ClarnetteRM, TaddeiK, MartinsG, PatonA, et al. (2002) Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment. Neurobiol Aging 23: 55–58.

46. HelisalmiS, HiltunenM, MannermaaA, KoivistoAM, LehtovirtaM, et al. (2000) Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease? Neurosci Lett 278: 65–68.

47. GuerreiroRJ, BaqueroM, BlesaR, BoadaM, BrasJM, et al. (2010) Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 31: 725–731.

48. MattilaKM, ForsellC, PirttilaT, RinneJO, LehtimakiT, et al. (1998) The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease. Ann Neurol 44: 965–967.

49. AldudoJ, BullidoMJ, FrankA, ValdiviesoF (1998) Missense mutation E318G of the presenilin-1 gene appears to be a nonpathogenic polymorphism. Ann Neurol 44: 985–986.

50. GoldmanJS, JohnsonJK, McElligottK, SuchowerskyO, MillerBL, et al. (2005) Presenilin 1 Glu318Gly polymorphism: interpret with caution. Arch Neurol 62: 1624–1627.

51. KauweJS, CruchagaC, KarchCM, SadlerB, LeeM, et al. (2011) Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One 6: e15918.

52. JinSC, PastorP, CooperB, CervantesS, BenitezBA, et al. (2012) Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimers Res Ther 4: 34.

53. SchymickJC, YangY, AndersenPM, VonsattelJP, GreenwayM, et al. (2007) Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry 78: 754–756.

54. KambohMI, SangheraDK, FerrellRE, DeKoskyST (1995) APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat Genet 10: 486–488.

55. RodriguezE, MateoI, InfanteJ, LlorcaJ, BercianoJ, et al. (2006) Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele. J Neurol 253: 181–185.

56. ReimanEM, WebsterJA, MyersAJ, HardyJ, DunckleyT, et al. (2007) GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54: 713–720.

57. WijsmanEM, PankratzND, ChoiY, RothsteinJH, FaberKM, et al. (2011) Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 7: e1001308.

58. KeenanBT, ShulmanJM, ChibnikLB, RajT, TranD, et al. (2012) A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 21: 2377–2388.

59. KnappenbergerKS, TianG, YeX, Sobotka-BrinerC, GhanekarSV, et al. (2004) Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry 43: 6208–6218.

60. MurayamaO, MurayamaM, HondaT, SunX, NihonmatsuN, et al. (1999) Twenty-nine missense mutations linked with familial Alzheimer's disease alter the processing of presenilin 1. Prog Neuropsychopharmacol Biol Psychiatry 23: 905–913.

61. HashimotoY, TsukamotoE, NiikuraT, YamagishiY, IshizakaM, et al. (2004) Amino- and carboxyl-terminal mutants of presenilin 1 cause neuronal cell death through distinct toxic mechanisms: Study of 27 different presenilin 1 mutants. J Neurosci Res 75: 417–428.

62. De JagerPL, ShulmanJM, ChibnikLB, KeenanBT, RajT, et al. (2012) A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging 33: 1017 e1011–1015.

63. McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944.

64. BergL, McKeelDWJr, MillerJP, StorandtM, RubinEH, et al. (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55: 326–335.

65. DruleyTE, VallaniaFL, WegnerDJ, VarleyKE, KnowlesOL, et al. (2009) Quantification of rare allelic variants from pooled genomic DNA. Nat Methods 6: 263–265.

66. HallerG, DruleyT, VallaniaFL, MitraRD, LiP, et al. (2012) Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. Hum Mol Genet 21: 647–655.

67. VallaniaFL, DruleyTE, RamosE, WangJ, BoreckiI, et al. (2010) High-throughput discovery of rare insertions and deletions in large cohorts. Genome Res 20: 1711–1718.

68. PriceAL, PattersonNJ, PlengeRM, WeinblattME, ShadickNA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904–909.

69. CooperGM, GoodeDL, NgSB, SidowA, BamshadMJ, et al. (2010) Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat Methods 7: 250–251.

70. CooperGM, StoneEA, AsimenosG, GreenED, BatzoglouS, et al. (2005) Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 15: 901–913.

71. HaroldD, AbrahamR, HollingworthP, SimsR, GerrishA, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088–1093.